The company provides active pharmaceutical ingredients, Pyramax (an anti-malarial drug), and drugs for treating hypercholesterolemia, knee osteoarthritis, shoulder periarthritis, and surgical adhesion barriers, plus prescription drugs, wound dressings, health functional food, and over-the-counter products. The company maintains a diversified portfolio spanning generic antibiotics to specialized therapeutics, positioning itself as a vertically-integrated domestic Korean pharmaceutical player.
Cyborg Score Rationale
Revenue grew 10.4% year-over-year in 2024 to $162.2M with strong net income growth of 73.2%, demonstrating operational improvement. However, the company underperformed both its industry and the broader market over the past year, indicating competitive headwinds despite profitability gains.
Top Insights
Diversified product portfolio spanning antibiotics, antivirals, anticancer, and specialty therapeutic areas reduces dependency on single drug categories
Strong 2024 net income growth (73.2%) indicates margin expansion and operational leverage despite modest revenue growth
International export presence in ~50 countries provides growth runway beyond domestic Korean market maturity
Underperformance versus both KR pharma sector and broader market suggests competitive margin pressure or market share loss